After having built the world’s largest drug development pipeline for the most neglected diseases, DNDi has unveiled plans for a more flexible, dynamic portfolio approach, integrating various operating models to better respond to the needs of patients, notably in low- and middle-income countries. The plan also paves the way for new diseases to be taken up in DNDi’s portfolio.

In the Business Plan for 2015-2023, DNDi remains committed to developing treatments for African sleeping sickness, leishmaniasis, and Chagas disease as well as filarial diseases and paediatric HIV. DNDi is also launching new research and development (R&D) projects for hepatitis C and mycetoma, two very different diseases that share one key challenge: the existing system of biomedical innovation has failed to deliver safe, effective, quality products that are affordable to poor populations.